Tom Nolan reviews this week’s research Many people with osteoporosis are unable to tolerate oral bisphosphonates—many others would prefer a six monthly denosumab injection to a once weekly pill that ...

At the recent SEC meeting for analgesics and rheumatology, the expert panel reviewed the proposed Phase I study protocol of ...

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients with ...

Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.